Athenex Inc is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. Its current clinical pipeline is derived from Orascovery, based on a P-glycoprotein (P-gp) pump inhibitor, Src Kinase inhibition, T-cell receptor-engineered T-cells, and arginine deprivation therapy...
look at this amazing opportunity! Price fell right onto the buy line! Average wall street analyst price projection is $18.
It is a correction and will rock to sky again, at this price it is investment.
Close to earnings, fundamental seems solid Waiting for confirmation Entry price: 12 Stop loss: 11.20 Target price 14.50
Nasdaq:ATNX Athenex, Inc Last News: Athenex partner in China on go to launch TAEST therapy studies; shares up 2% Athenex (ATNX +2.1%) announces that commercialization partner Xiangxue Pharmaceutical Company's subsidiary Xiangxue Life Sciences has received regulatory sign-off in China to start registration studies of T-cell receptor Affinity Enhanced Specific...